Conformational compatibility as a basis of differential affinities of tachykinins for the neurokinin-1 receptor

被引:36
作者
Huang, RRC [1 ]
Huang, D [1 ]
Strader, CD [1 ]
Fong, TM [1 ]
机构
[1] MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,RAHWAY,NJ 07065
关键词
D O I
10.1021/bi00050a030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neurokinin-1 receptor is characterized by sub-nanomolar affinity for substance P and 30-100 nM affinity for other substance P-related peptides, including neurokinin B and septide. We have characterized a neurokinin-1 receptor mutant containing a Y216A substitution in the fifth transmembrane segment. This receptor mutant binds substance P with sub-nanomolar affinity but loses much of its peptide discrimination capability, exhibiting 1-2 nM binding affinity for other tachykinins. Kinetic measurements of ligand binding indicate that the increased binding affinity of neurokinin B and septide for the Y216A mutant compared to the wild-type receptor is due to a 100-fold increase in the association rate constant without appreciable change in the dissociation rate constant. The substantially increased association rate constant for the Y216A mutant suggests that the mutant receptor is probably more flexible in accommodating the approaching peptide molecule. It is proposed that a major determinant of peptide specificity for the wild-type neurokinin-1 receptor is the overall conformational compatibility between the receptor and the ligand, rather than residue-specific interactions with the divergent N-terminal residues of different peptides. Furthermore, the highly conserved nature of Tyr-216 in the G protein coupled receptor family suggests that this residue may also play an important role in the receptor activation process in general.
引用
收藏
页码:16467 / 16472
页数:6
相关论文
共 40 条
[1]  
BRODBECK RM, 1995, MOL PHARMACOL, V47, P1065
[2]  
CASCIERI MA, 1994, J BIOL CHEM, V269, P6587
[3]  
CASCIERI MA, 1992, MOL PHARMACOL, V42, P458
[4]   FLAP OPENING IN HIV-1 PROTEASE SIMULATED BY ACTIVATED MOLECULAR-DYNAMICS [J].
COLLINS, JR ;
BURT, SK ;
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (04) :334-338
[5]   CALCULATING RECEPTOR NUMBER FROM BINDING EXPERIMENTS USING SAME COMPOUND AS RADIOLIGAND AND COMPETITOR [J].
DEBLASI, A ;
OREILLY, K ;
MOTULSKY, HJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (06) :227-229
[6]   ENGINEERING GALACTOSE-BINDING ACTIVITY INTO A C-TYPE MANNOSE-BINDING PROTEIN [J].
DRICKAMER, K .
NATURE, 1992, 360 (6400) :183-186
[7]  
EDMONDSALT X, 1993, EUR J PHARMACOL, V250, P403
[8]  
FONG TM, 1992, J BIOL CHEM, V267, P25668
[9]  
FONG TM, 1992, J BIOL CHEM, V267, P25664
[10]  
FONG TM, 1994, J BIOL CHEM, V269, P14957